Ignite Creation Date:
2025-12-24 @ 5:04 PM
Ignite Modification Date:
2026-02-21 @ 8:27 PM
Study NCT ID:
NCT00681850
Status:
COMPLETED
Last Update Posted:
2020-01-22
First Post:
2008-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
Sponsor:
AstraZeneca
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
D3560L00071
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Eugène Vissers, MD, Therapeutic Area Leader Cardivascular and Diabetes.
Old Organization:
AstraZeneca Pharmaceuticals